Nagasaka M, Balmanoukian AS, Madison R, Zhang SS, et al. Amivantamab (JNJ-61186372) induces clinical, biochemical, molecular, and radiographic response in a treatment-refractory NSCLC patient harboring amplified triple EGFR mutations (L858R/ T790M/G796S) in cis. Lung Cancer 2022;164:52-55.
PMID: 35032819